CA3073392C - Cytocidal agent - Google Patents

Cytocidal agent Download PDF

Info

Publication number
CA3073392C
CA3073392C CA3073392A CA3073392A CA3073392C CA 3073392 C CA3073392 C CA 3073392C CA 3073392 A CA3073392 A CA 3073392A CA 3073392 A CA3073392 A CA 3073392A CA 3073392 C CA3073392 C CA 3073392C
Authority
CA
Canada
Prior art keywords
peptide
cngb3
cell
amino acids
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3073392A
Other languages
English (en)
French (fr)
Other versions
CA3073392A1 (en
Inventor
Kazuhiro Sugihara
Naohiro Kanayama
Yuichiro ONODERA
Toshiaki Shibata
Michiko Fukuda
Motohiro NONAKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujita Health University
Original Assignee
Fujita Health University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujita Health University filed Critical Fujita Health University
Publication of CA3073392A1 publication Critical patent/CA3073392A1/en
Application granted granted Critical
Publication of CA3073392C publication Critical patent/CA3073392C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3073392A 2017-08-24 2018-08-23 Cytocidal agent Active CA3073392C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017161556A JP6613499B2 (ja) 2017-08-24 2017-08-24 細胞殺傷剤
JP2017-161556 2017-08-24
PCT/JP2018/031136 WO2019039540A1 (ja) 2017-08-24 2018-08-23 細胞殺傷剤

Publications (2)

Publication Number Publication Date
CA3073392A1 CA3073392A1 (en) 2019-02-28
CA3073392C true CA3073392C (en) 2023-02-21

Family

ID=65438932

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3073392A Active CA3073392C (en) 2017-08-24 2018-08-23 Cytocidal agent

Country Status (9)

Country Link
US (2) US11357819B2 (OSRAM)
EP (1) EP3738601A4 (OSRAM)
JP (1) JP6613499B2 (OSRAM)
KR (1) KR102427844B1 (OSRAM)
CN (1) CN111065403B (OSRAM)
AU (1) AU2018322305B2 (OSRAM)
CA (1) CA3073392C (OSRAM)
SG (1) SG11202001484QA (OSRAM)
WO (1) WO2019039540A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6613499B2 (ja) 2017-08-24 2019-12-04 学校法人藤田学園 細胞殺傷剤
AU2018402356B2 (en) 2018-01-09 2021-05-20 Fujita Academy Cytocidal agent
WO2022234346A1 (en) * 2021-05-07 2022-11-10 Twinpig Biolab, Inc. Peptides targeting macrophages, and conjugates, compositions, and uses thereof
CN115725968A (zh) * 2022-11-18 2023-03-03 东莞宜安科技股份有限公司 一种生物医用钛合金表面的复合涂层及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
CA2634934A1 (en) * 2005-12-23 2007-07-05 The Burnham Institute For Medical Research Endometriosis cell targeting peptide and uses thereof
US20120142606A1 (en) * 2009-04-01 2012-06-07 Ingo Schmidt-Wolf Tumor targeting peptides, therapeutic and diagnostic compositions compressing the peptides
WO2011027312A1 (en) 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. NOVEL TUMOR MARKERS SELECTED FROM A GROUP OF cAMP-REGULATORY PATHWAY MEMBERS
EP2515944B1 (en) * 2009-12-23 2020-04-22 Sanford-Burnham Medical Research Institute Methods and compositions related to annexin 1-binding compounds
US9107878B2 (en) 2010-04-06 2015-08-18 Exocyte Therapeutics Pte, Ltd Methods of treating cancer
US20160067357A1 (en) * 2012-08-17 2016-03-10 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
US9783576B2 (en) * 2013-06-11 2017-10-10 Sanford-Burnham Medical Research Institute Compositions and methods for targeted endometriosis treatment
US10338068B2 (en) * 2013-07-08 2019-07-02 The Trustees Of Columbia University In The City Of New York Selection of biological objects
JPWO2015041019A1 (ja) * 2013-09-18 2017-03-02 国立大学法人京都大学 子宮内膜症様細胞の作製方法および子宮内膜症モデル動物
ES2772348T3 (es) 2014-12-19 2020-07-07 Ablynx Nv Dímeros de Nanobody con uniones cisteína
RU2571551C1 (ru) 2015-04-16 2015-12-20 Закрытое акционерное общество "ПЕПТЕК" Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
JP2017161556A (ja) 2017-06-27 2017-09-14 パイオニア株式会社 位置認識装置、制御方法、プログラム、及び記憶媒体
JP6613499B2 (ja) 2017-08-24 2019-12-04 学校法人藤田学園 細胞殺傷剤

Also Published As

Publication number Publication date
EP3738601A1 (en) 2020-11-18
CN111065403A (zh) 2020-04-24
US20200289608A1 (en) 2020-09-17
AU2018322305B2 (en) 2021-05-20
SG11202001484QA (en) 2020-03-30
CN111065403B (zh) 2023-09-26
KR102427844B1 (ko) 2022-07-29
WO2019039540A1 (ja) 2019-02-28
KR20200031670A (ko) 2020-03-24
US20220280596A1 (en) 2022-09-08
EP3738601A4 (en) 2021-06-16
CA3073392A1 (en) 2019-02-28
US11357819B2 (en) 2022-06-14
AU2018322305A1 (en) 2020-03-05
JP2019038772A (ja) 2019-03-14
JP6613499B2 (ja) 2019-12-04

Similar Documents

Publication Publication Date Title
US20220280596A1 (en) Cytocidal agent
Hsu et al. The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling
Kim et al. Tumor-suppressive effect of a telomerase-derived peptide by inhibiting hypoxia-induced HIF-1α-VEGF signaling axis
ES2844874T3 (es) Complejo de proteína de leche y ácido graso
JP2022519777A (ja) 処置誘導性の胃腸傷害を防止又は処置する方法
Yang et al. Upregulation of Parkinson's disease-associated protein alpha-synuclein suppresses tumorigenesis via interaction with mGluR5 and gamma-synuclein in liver cancer
Leskov et al. CRM1 protein-mediated regulation of nuclear clusterin (nCLU), an ionizing radiation-stimulated, Bax-dependent pro-death factor
Kim et al. Clusterin interaction with Bcl-xL is associated with seizure-induced neuronal death
KR101401891B1 (ko) 테모졸로미드 및 발프로산을 함께 이용하는 항암적 용도
Ghatak et al. Heat shock protein 70 in penile neurovascular regeneration requires cystathionine gamma-lyase
CA3087744C (en) CYTOCIDAL AGENT
HK40023962A (zh) 细胞杀伤剂
US9581598B2 (en) Diagnosis and treatment of brain tumor
Wang et al. Construction of human LRIG1-TAT fusions and TAT-mediated LRIG1 protein delivery
Midavaine et al. CCR2 silencing in sensory neurons blocks bone cancer progression
HK40032209A (en) Cytocide
Jin et al. Epithelial ovarian cancer: feasibility of image-guided intratumoral radiofrequency hyperthermia-enhanced direct gene therapy
JP2019510015A (ja) Ｂｃｌ−２ ｌ１０／ｉｐ３受容体の相互作用の阻害剤
Martinez Andrade The targeted delivery of G3 peptide drug conjugates in prostate cancer
Zhou Selective knockdown of misfolded SOD1 as a therapy for amyotrophic lateral sclerosis
Chiou Redefining the Role of H-Ferritin in the Brain
JP2020030120A (ja) 疾患発症可能性の評価方法
TW201725048A (zh) 抗菌胜肽tp4治療癌症之用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200219

EEER Examination request

Effective date: 20200219

EEER Examination request

Effective date: 20200219

EEER Examination request

Effective date: 20200219

EEER Examination request

Effective date: 20200219